Contents lists available at ScienceDirect



## International Journal of Surgery

journal homepage: www.elsevier.com/locate/ijsu



## Original Research

# Trauma patients with lower extremity and pelvic fractures: Should *anti*-factor Xa trough level guide prophylactic enoxaparin dose?<sup> $\star$ </sup>



Navpreet K. Dhillon, MD, Eric J.T. Smith, Emma Gillette, Russell Mason, PharmD, Galinos Barmparas, MD, Bruce L. Gewertz, MD, Eric J. Ley, MD<sup>\*</sup>

Department of Surgery, Division of Trauma and Critical Care, Cedars-Sinai Medical Center, Los Angeles, CA, United States

#### ARTICLE INFO

Keywords: Deep vein thrombosis Enoxaparin Extremity fracture Pelvic fracture Trauma Venous thromboembolism

#### ABSTRACT

*Background:* Adequate venous thromboembolism (VTE) prophylaxis is essential after trauma, especially in patients with lower extremity and/or pelvic fractures. We sought to investigate if prophylactic enoxaparin dosed by *anti-*Xa trough levels could reduce clinically evident VTE in trauma patients with lower extremity or pelvic injury.

*Methods*: Prospective data was collected on trauma patients admitted for at least two days with any lower extremity and/or pelvic fracture and who received enoxaparin for VTE prophylaxis between October 2013 and January 2016. Patients in the control cohort received enoxaparin at 30 mg twice daily. Patients in the adjustment cohort had *anti*-Xa trough levels measured after three or more consecutive doses of enoxaparin. Those with a trough level of 0.1 IU/mL or lower had their dosage increased by 10-mg increments.

*Results*: Of the 159 patients included, 58 (36.5%) were monitored with *anti*-Xa trough levels. The cohorts were similar in age, sex, regional AIS, ISS score, ICU and hospital length of stay, proportion of patients with diagnostic testing for VTE, and time to first enoxaparin dose. Initial enoxaparin dosing in the majority of patients (84.5%) who had *anti*-Xa trough levels measured was subprophylactic. Patients receiving enoxaparin dosed by *anti*-Xa trough level had a significantly lower VTE rate than those who did not (1.7% v. 13.9%, p = 0.03).

*Conclusions*: Prophylactic enoxaparin adjusted by *anti*-factor Xa level may lead to a decreased rate of clinically evident VTE among trauma patients with lower extremity and/or pelvic fractures. Our findings indicate that the initial dose of enoxaparin was frequently too low.

#### 1. Background

Venous thromboembolism (VTE) poses a significant challenge after trauma. Patients diagnosed with VTE tend to have worse outcomes with longer hospital stays, disability at discharge, costs, and mortality [1–4]. The rate of VTE varies considerably within the literature, ranging from 11.8% to 63% for deep vein thrombosis (DVT) and 1.5%–22% for pulmonary emboli (PE) [5–7]. Given the clinical and economic implications of VTE, there has been considerable interest in understanding the risk factors for VTE and developing methods to reduce their occurrence [8–10]. One population highly susceptible to developing VTE is trauma patients with lower extremity and pelvic fractures [11] as these patients meet Virchow's triad for VTE development: endothelial injury, venous stasis, and the presence of a hypercoagulable state. In addition, these patients are frequently immobile, which increases the risk for VTE [12,13].

For patients with lower extremity and/or pelvic fractures, mobility protocols and utilization of pneumatic compression devices may reduce the occurrence of VTE, however, more reliable evidence is needed to clearly demonstrate the efficacy of these measures [14,15]. Pharmacologic thromboprophylaxis reduces the risk for DVT, but similar to mobility protocols and mechanical prophylaxis, no reduction in the incidence of PE has been demonstrated [16]. Other studies have suggested that pharmacologic thromboprophylaxis with low molecular weight heparin such as enoxaparin sodium is superior to unfractionated heparin in trauma patients [17,18]. Many centers administer enoxaparin sodium 30 mg twice daily, although there is evidence to suggest that this dose is inadequate [19]. Ko et al. appreciated a reduction in the incidence of VTE among trauma patients after titrating enoxaparin sodium dose specifically to anti-factor Xa trough levels. In addition, most patients required enoxaparin sodium 40 mg twice daily to reach the desired anti-factor Xa trough level [20]. While the role of

https://doi.org/10.1016/j.ijsu.2018.01.023

Received 16 October 2017; Received in revised form 30 December 2017; Accepted 4 January 2018 Available online 31 January 2018 1743-9191/ © 2018 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

<sup>\*</sup> This manuscript was an e-poster presentation at the 88th Scientific Session of the Pacific Coast Surgical Association in Indian Wells, CA, February 17–20, 2017.

<sup>\*</sup> Corresponding author. Cedars-Sinai Medical Center, Department of Surgery, 8700 Beverly Blvd, Suite 8215NT, Los Angeles, CA 90048, United States.

E-mail addresses: Navpreet.Dhillon@cshs.org (N.K. Dhillon), Eric.Smith@cshs.org (E.J.T. Smith), Emma.Gillette@cshs.org (E. Gillette), Russell.Mason@cshs.org (R. Mason), Galinos.Barmparas@cshs.org (G. Barmparas), Bruce.Gewertz@cshs.org (B.L. Gewertz), Eric.Ley@cshs.org (E.J. Ley).

dosing enoxaparin sodium with *anti*-factor Xa trough levels has been shown to be effective in trauma patients overall, its utility in specific trauma populations has not been assessed. We hypothesized that in trauma patients with lower extremity and/or pelvic fractures, a population who is particularly susceptible to VTE, dosing enoxaparin sodium by *anti*-factor Xa trough levels could reduce the clinically evident, or symptomatic, VTE rate.

#### 2. Methods

We retrospectively reviewed prospectively collected data on trauma patients with any lower extremity and/or pelvic fracture admitted for at least two days who received enoxaparin for VTE prophylaxis at an urban level 1 trauma center between October 2013 and January 2016. Patients with a history of renal failure, a creatinine clearance (CrCl) less than 30 mL/min, or a preexisting VTE were excluded. Patients in the control cohort (CONTROL) from October 2013 to July 2014 received enoxaparin at 30 mg twice daily, while patients in the adjustment cohort (ADJUST) from August 2014 to January 2016 were initially given enoxaparin at 30 mg twice daily with dose adjustments according to anti-factor Xa trough levels. All patients were initially placed on 30 mg twice daily dosing irrespective of body weight. Enoxaparin initiation was at the discretion of the rounding trauma service. Anti-factor Xa trough levels were measured after three or more consecutive doses of enoxaparin. A trough level 0.1 IU/mL or less was deemed to be subprophylactic and the patient's subsequent enoxaparin dose was increased by a 10 mg increment. Per protocol, the dosage was also to be decreased by 10 mg increments if the trough level was above 0.2 IU/mL until the patient was at the appropriate levels, although no patients in ADJUST exceeded 0.2 IU/mL. Per protocol, the trough level was repeated after three or more consecutive administrations at the newer dose with subsequent dose adjustments as needed. Trough levels were monitored and dose adjustments were made until either the patient reached an appropriate trough level between 0.11 and 0.2 IU/mL or the patient was discharged.

The primary outcome was VTE, which was diagnosed with either duplex ultrasonography of the entire extremity, chest computed tomography angiogram (CTA), or lung ventilation-perfusion (VQ) scan to detect deep venous thrombosis (DVT) or a pulmonary embolus (PE). Studies were ordered at the discretion of the rounding trauma service based on clinical suspicion for either a DVT or PE. For the purposes of this study, a proximal DVT was defined as any DVT from the common femoral vein to the popliteal vein, and a distal DVT as any DVT distal to the popliteal vein.

Data including patient demographics, mechanism of injury, injury severity scores, hospital and ICU length of stays (LOS), details regarding enoxaparin administration, anti-factor Xa trough levels, and results of imaging studies were collected and compared between the CONTROL and ADJUST cohorts. Data were analyzed using IBM SPSS statistics for Windows, version 23 (IBM Corp., Armonk, N.Y., USA) and are summarized as percentages for categorical variables and means with standard deviations (SD) and medians with interquartile range (IQR) for continuous variables. Comparisons of continuous variables were conducted using the Mann-Whitney U Test. All variables were noted to be nonparametric with the exception of Body Mass Index (BMI) and Body Surface Area (BSA). Categorical variables and proportions were compared using Pearson  $\chi$  [2] test or Fisher's exact test. A P-value less than 0.05 was considered statistically significant. This study was approved by our Institutional Review Board and registered at ResearchRegistry. com. This work has been reported in line with the Strengthening the Reporting of Cohort Studies in Surgery (STROCSS) criteria [21].

#### 3. Results

There were 101 patients in the CONTROL cohort and 58 in the ADJUST cohort. The median age was 37 years and the majority of

Table 1

Comparison of baseline characteristics and outcomes between ADJUST and CONTROL.

Mean $\pm$ SD         40.8 $\pm$ 17.9         40.1 $\pm$ 17.6         41.2 $\pm$ 18.2           Median (UQR)         37 (27-50)         34 (26-52)         38 (27.5-48.5)         0.69           Mace, No. (%)         111 (69.8)         37 (63.8)         74 (73.3)         0.28           Race, No. (%)         111 (6.9)         5 (8.6)         6 (5.9)         0.36           Black         27 (17.0)         14 (24.1)         13 (12.9)         White         84 (52.8)         30 (51.7)         54 (53.5)           Hispanic         24 (15.1)         6 (10.3)         18 (17.8)         0.74           Other         7 (4.4)         2 (3.4)         5 (5.0)           Unknown         6 (3.8)         1 (1.7)         5 (5.0)           BMI          24.8 $\pm$ 5.0         24.6 $\pm$ 5.4         24.9 $\pm$ 4.7         0.74           Median (QR)         24.1         24.1         24.3         (21.3-27.4)         BSA           Sore         I.9 $\pm$ 0.2         1.9 $\pm$ 0.2         1.9 $\pm$ 0.2         0.91         Median (QR)         0         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (	Characteristic	Total (n = 159)	$\begin{array}{l} \text{ADJUST} \\ (n = 58) \end{array}$	$\begin{array}{l} \text{CONTROL} \\ (n = 101) \end{array}$	P value
Mean $\pm$ SD         40.8 $\pm$ 17.9         40.1 $\pm$ 17.6         41.2 $\pm$ 18.2           Median (UQR)         37 (27-50)         34 (26-52)         38 (27.5-48.5)         0.69           Mace, No. (%)         111 (69.8)         37 (63.8)         74 (73.3)         0.28           Race, No. (%)         111 (6.9)         5 (8.6)         6 (5.9)         0.36           Black         27 (17.0)         14 (24.1)         13 (12.9)         White         84 (52.8)         30 (51.7)         54 (53.5)           Hispanic         24 (15.1)         6 (10.3)         18 (17.8)         0.74           Other         7 (4.4)         2 (3.4)         5 (5.0)           Unknown         6 (3.8)         1 (1.7)         5 (5.0)           BMI          24.8 $\pm$ 5.0         24.6 $\pm$ 5.4         24.9 $\pm$ 4.7         0.74           Median (QR)         24.1         24.1         24.3         (21.3-27.4)         BSA           Sore         I.9 $\pm$ 0.2         1.9 $\pm$ 0.2         1.9 $\pm$ 0.2         0.91         Median (QR)         0         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (	Age, y				
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Mean ± SD	$40.8 \pm 17.9$	$40.1 \pm 17.6$	$41.2 \pm 18.2$	
Race, No. (%)       Asian       11 (6.9)       5 (8.6)       6 (5.9)       0.36         Black       27 (17.0)       14 (24.1)       13 (12.9)         White       84 (52.8)       30 (51.7)       54 (53.5)         Hispanic       24 (15.1)       6 (10.3)       18 (17.8)         Other       7 (4.4)       2 (3.4)       5 (5.0)         BMI       Mean $\pm$ SD       24.8 $\pm$ 5.0       24.6 $\pm$ 5.4       24.9 $\pm$ 4.7       0.74         Median (IQR)       24.1       24.1       24.3       (21.3–27.6)       (21.6–28.3)       (21.3–27.4)         BSA, m <sup>2</sup> (21.3–27.6)       1.9 $\pm$ 0.2       1.9 $\pm$ 0.2       0.91       Median (IQR)       1.9 (1.7–2.0)       1.9 (1.7–2.0)       1.9 (1.7–2.0)         Median (IQR)       1.9 (1.7–2.0)       1.9 (1.7–2.0)       1.9 (1.7–2.0)       1.9 (1.7–2.0)       1.9 (1.7–2.0)         ASS core       (93.8–155.8)       (93.8–171.6)       (94.9–149.1)       Alse         AIS Score       Head/Neck       Mean $\pm$ SD       0.9 $\pm$ 1.5       1.1 $\pm$ 1.6       0.9 $\pm$ 1.5       0.34         Median (IQR)       0 (0–2)       0 (0–3)       0 (0–1)       0 (0–1)       C27         Mean $\pm$ SD       0.4 $\pm$ 0.8       0.5 $\pm$ 1.0       0.3 $\pm$	Median (IQR)	37 (27-50)	34 (26–52)	38 (27.5-48.5)	0.69
Asian         11 (6.9)         5 (8.6)         6 (5.9)         0.36           Black         27 (17.0)         14 (24.1)         13 (12.9)           White         84 (52.8)         30 (51.7)         54 (53.5)           Hispanic         24 (15.1)         6 (10.3)         18 (17.8)           Other         7 (4.4)         2 (3.4)         5 (5.0)           Unknown         6 (3.8)         1 (1.7)         5 (5.0)           BMI	Male, No. (%)	111 (69.8)	37 (63.8)	74 (73.3)	0.28
Black         27 (17.0)         14 (24.1)         13 (12.9)           White         84 (52.8)         30 (51.7)         54 (53.5)           Hispanic         24 (15.1)         6 (10.3)         18 (17.8)           Other         7 (4.4)         2 (3.4)         5 (5.0)           BMI         (21.3-27.6)         (21.6-28.3)         (21.3-27.4)           BSA, m <sup>2</sup> (21.3-27.6)         (21.6-28.3)         (21.3-27.4)           BSA, m <sup>2</sup> (21.3-27.6)         1.9 ± 0.2         1.9 ± 0.2         0.9 ± 0.2           Median (IQR)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)           Median (IQR)         121.3         132.9         118.9         0.28           Median (IQR)         121.3         132.9         118.9           Median (IQR)         0 (0-2)         0 (0-3)         0 (0-1)           Face         Mean ± SD         0.9 ± 1.5         1.1 ± 1.6         0.9 ± 1.5         0.34           Median (IQR)         0 (0-2)         0 (0-3)         0 (0-3)         0 (0-3)           Kean ± SD         0.4 ± 0.8         0.5 ± 1.0         0.3 ± 0.8         0.32           Median (IQR)         0 (0-2)         0 (0-3)         0 (0-3)	Race, No. (%)				
White         84 (52.8)         30 (51.7)         54 (53.5)           Hispanic         24 (15.1)         6 (10.3)         18 (17.8)           Other         7 (4.4)         2 (3.4)         5 (5.0)           BMI              Mean $\pm$ SD         24.8 $\pm$ 5.0         24.6 $\pm$ 5.4         24.9 $\pm$ 4.7         0.74           Median (IQR)         24.1         24.1         24.3         (21.3-27.6)         (21.6-28.3)         (21.3-27.4)           BSA, m <sup>2</sup> .19 $\pm$ 0.2         1.9 $\pm$ 0.2         0.91         Median (IQR)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         CPC1, mL/min           Mean $\pm$ SD         1.30.4 $\pm$ 5.8.7         139.1 $\pm$ 66.0         125.4 $\pm$ 53.8         0.28           Median (IQR)         121.3         132.9         118.9         (93.8-155.8)         (93.8-171.6)         (94.9-149.1)           AlS Score           Mean $\pm$ SD         0.9 $\pm$ 1.5         1.1 $\pm$ 1.6         0.9 $\pm$ 1.5         0.34           Median (IQR)         0 (0-2)         0 (0-3)         0 (0-1)         10         10           Face           Meadian (IQR)         0 (0-2)         0 (0-2)         0 (0-2)	Asian	11 (6.9)	5 (8.6)	6 (5.9)	0.36
Hispanic         24 (15.1)         6 (10.3)         18 (17.8)           Other         7 (4.4)         2 (3.4)         5 (5.0)           Unknown         6 (3.8)         1 (1.7)         5 (5.0)           BMI         Mean $\pm$ SD         24.8 $\pm$ 5.0         24.6 $\pm$ 5.4         24.9 $\pm$ 4.7         0.74           Median (IQR)         24.1         24.1         24.3         (21.3-27.6)         (21.6-28.3)         (21.3-27.4)           BSA, m <sup>2</sup> (21.3-27.6)         (21.6-28.3)         (21.3-27.4)         0.74           Median (IQR)         1.9 $\pm$ 0.2         1.9 $\pm$ 0.2         1.9 $\pm$ 0.2         0.91           Median (IQR)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.7 (1.7-2.0)           CrCl, mL/min         Mean $\pm$ SD         130.4 $\pm$ 58.7         139.1 $\pm$ 66.0         125.4 $\pm$ 53.8         0.28           Median (IQR)         121.3         132.9         118.9         0.4           Mean $\pm$ SD         0.9 $\pm$ 1.5         1.1 $\pm$ 1.6         0.9 $\pm$ 1.5         0.34           Median (IQR)         0 (0-2)         0 (0-3)         0 (0-1)         0 (0-1)           Chest         Mean $\pm$ SD         1.4 $\pm$ 1.7         1.6 $\pm$ 1.6         1.3 $\pm$ 1.7         0.27	Black	27 (17.0)	14 (24.1)	13 (12.9)	
Other         7 (4.4)         2 (3.4)         5 (5.0)           Unknown         6 (3.8)         1 (1.7)         5 (5.0)           BMI         Mean $\pm$ SD         24.8 $\pm$ 5.0         24.6 $\pm$ 5.4         24.9 $\pm$ 4.7         0.74           Median (IQR)         24.1         24.1         24.3         (21.3-27.4)         BSA, m <sup>2</sup> Mean $\pm$ SD         1.9 $\pm$ 0.2         1.9 $\pm$ 0.2         1.9 $\pm$ 0.2         0.91           Median (IQR)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         C1.9 (1.7-2.0)           CCI, mL/min         Mean $\pm$ SD         130.4 $\pm$ 58.7         139.1 $\pm$ 66.0         125.4 $\pm$ 53.8         0.28           Median (IQR)         121.3         132.9         118.9         (93.8-155.8)         (93.8-171.6)         (94.9-149.1)           Als Score         Head/Neck         Mean $\pm$ SD         0.4 $\pm$ 0.8         0.5 $\pm$ 1.0         0.3 $\pm$ 0.8         0.32           Median (IQR)         0 (0-2)         0 (0-3)         0 (0-1)         0         0           Chean $\pm$ SD         1.4 $\pm$ 1.7         1.6 $\pm$ 1.6         1.3 $\pm$ 1.7         0.27           Median (IQR)         0 (0-2)         0 (0-2)         0 (0-3)         0 (0-3)           Abdomen/Pelvis	White	84 (52.8)	30 (51.7)	54 (53.5)	
Unknown         6 (3.8)         1 (1.7)         5 (5.0)           BMI         Median (IQR)         24.8 $\pm$ 5.0         24.6 $\pm$ 5.4         24.9 $\pm$ 4.7         0.74           Median (IQR)         24.1         24.1         24.3         (21.3-27.4)         BSA, m <sup>2</sup> Mean $\pm$ SD         1.9 $\pm$ 0.2         1.9 $\pm$ 0.2         1.9 $\pm$ 0.2         0.91         Median (IQR)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         0.91           Median (IQR)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         1.9 (1.7-2.0)         0.91           Median (IQR)         121.3         132.9         118.9         0.28         0.28         0.28         0.24 $\pm$ 53.8         0.28           Mean $\pm$ SD         0.4 $\pm$ 0.8         0.5 $\pm$ 1.0         0.3 $\pm$ 0.34         Median (IQR)         0 (0-2)         0 (0-3)         0 (0-1)           Face         Mean $\pm$ SD         0.4 $\pm$ 0.8         0.5 $\pm$ 1.0         0.3 $\pm$ 0.8         0.32           Median (IQR)         0 (0-2)         0 (0-3)         0 (0-3)         0 (0-3)           Abdomen/Pelvis         Mean $\pm$ SD         1.4 $\pm$ 1.7         1.6 $\pm$ 1.6         1.3 $\pm$ 1.7         0.27           Median (IQR)         0 (0-2)         0 (0-2)         0 (0-3) </td <td>Hispanic</td> <td>24 (15.1)</td> <td>6 (10.3)</td> <td>18 (17.8)</td> <td></td>	Hispanic	24 (15.1)	6 (10.3)	18 (17.8)	
BMI Mean $\pm$ SD 24.8 $\pm$ 5.0 24.6 $\pm$ 5.4 24.9 $\pm$ 4.7 0.74 Median (IQR) 24.1 24.3 (21.3-27.4) BSA, m <sup>2</sup> Mean $\pm$ SD 1.9 $\pm$ 0.2 1.9 $\pm$ 0.2 1.9 $\pm$ 0.2 0.91 Median (IQR) 1.9 (1.7-2.0) 1.9 (1.7-2.0) 1.9 (1.7-2.0) CrCl, mL/min Mean $\pm$ SD 130.4 $\pm$ 58.7 139.1 $\pm$ 66.0 125.4 $\pm$ 53.8 0.28 Median (IQR) 121.3 132.9 118.9 (93.8-171.6) (94.9-149.1) AIS Score Head/Neck Mean $\pm$ SD 0.9 $\pm$ 1.5 1.1 $\pm$ 1.6 0.9 $\pm$ 1.5 0.34 Median (IQR) 0 (0-2) 0 (0-3) 0 (0-1) Face Mean $\pm$ SD 0.4 $\pm$ 0.8 0.5 $\pm$ 1.0 0.3 $\pm$ 0.8 0.32 Median (IQR) 0 (0-0) 0 (0-0) 0 (0-0) Chest Mean $\pm$ SD 1.4 $\pm$ 1.7 1.6 $\pm$ 1.6 1.3 $\pm$ 1.7 0.27 Median (IQR) 0 (0-2) 0 (0-2) 0 (0-3) Abdomen/Pelvis Mean $\pm$ SD 1 $\pm$ 1.5 0.9 $\pm$ 1.4 1.1 $\pm$ 1.6 0.62 Median (IQR) 0 (0-2) 0 (0-2) 0 (0-3) Abdomen/Pelvis Mean $\pm$ SD 1 $\pm$ 1.5 0.9 $\pm$ 1.4 1.1 $\pm$ 1.6 0.62 Median (IQR) 3 (2-3) 3 (2-3) Scare Mean $\pm$ SD 1 $\pm$ 1.5 0.9 $\pm$ 1.4 1.1 $\pm$ 1.6 0.62 Median (IQR) 3 (2-3) 3 (2-3) Scare Mean $\pm$ SD 1.6 $\pm$ 0.8 $\pm$ 0.6 0.9 $\pm$ 0.6 0.94 Median (IQR) 1 (0-1) 1 (0-1) ISS Mean $\pm$ SD 19.6 $\pm$ 13.6 19.1 $\pm$ 11.0 19.9 $\pm$ 14.9 0.64 Median (IQR) 17 (10-27) 18 (10-24) 14 (9-29) Outcomes Hospital LOS, d Mean $\pm$ SD 15.7 $\pm$ 14.4 16.5 $\pm$ 16.9 15.3 $\pm$ 12.8 0.98 Median (IQR) 11 (6-20) 12 (6-22) 10 (7-19.5) ICU LOS, d Mean $\pm$ SD 6.9 $\pm$ 7.3 7.5 $\pm$ 7.3 6.6 $\pm$ 7.4 0.37 Median (IQR) 4 (2-9) 4 (3-12) 3.5 (2-7) Required ICU 112 (70.4) 42 (72.4) 70 (69.3) 0.82 care, n (%) Mortality, No. 1 (0.6) 0 1 (1.0) > 0.9	Other	7 (4.4)	2 (3.4)	5 (5.0)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Unknown	6 (3.8)	1 (1.7)	5 (5.0)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	BMI				
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Mean ± SD	$24.8 \pm 5.0$	$24.6 \pm 5.4$	$24.9 \pm 4.7$	0.74
$\begin{array}{llllllllllllllllllllllllllllllllllll$	Median (IQR)	24.1	24.1	24.3	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		(21.3-27.6)	(21.6-28.3)	(21.3-27.4)	
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	BSA, m <sup>2</sup>				
CrCl, mL/min       Mean $\pm$ SD       130.4 $\pm$ 58.7       139.1 $\pm$ 66.0       125.4 $\pm$ 53.8       0.28         Median (IQR)       121.3       132.9       118.9         (93.8-155.8)       (93.8-171.6)       (94.9-149.1)         AlS Score       Head/Neck       (94.9-149.1)         Mean $\pm$ SD       0.9 $\pm$ 1.5       1.1 $\pm$ 1.6       0.9 $\pm$ 1.5       0.34         Median (IQR)       0 (0-2)       0 (0-3)       0 (0-1)         Face       Mean $\pm$ SD       0.4 $\pm$ 0.8       0.5 $\pm$ 1.0       0.3 $\pm$ 0.8       0.32         Median (IQR)       0 (0-0)       0 (0-0)       0 (0-0)       Chool       0         Chest       Mean $\pm$ SD       1.4 $\pm$ 1.7       1.6 $\pm$ 1.6       1.3 $\pm$ 1.7       0.27         Median (IQR)       0 (0-2)       0 (0-2)       0 (0-3)       Chool       0         Abdomen/Pelvis       Mean $\pm$ SD       1 $\pm$ 1.5       0.9 $\pm$ 1.4       1.1 $\pm$ 1.6       0.62         Median (IQR)       1 $\pm$ 1.5       0.9 $\pm$ 1.4       1.1 $\pm$ 1.6       0.62         Median (IQR)       3 (2-3)       3 (2-3)       3 (2-3)       3 (2-3)         Extremity       Mean $\pm$ SD       0.9 $\pm$ 0.6       0.8 $\pm$ 0.6       0.9 $\pm$ 0.6       0.84	Mean ± SD	$1.9 \pm 0.2$	$1.9 \pm 0.2$	$1.9 \pm 0.2$	0.91
CrCl, mL/min       Mean $\pm$ SD       130.4 $\pm$ 58.7       139.1 $\pm$ 66.0       125.4 $\pm$ 53.8       0.28         Median (IQR)       121.3       132.9       118.9         (93.8-155.8)       (93.8-171.6)       (94.9-149.1)         AlS Score       Head/Neck       (94.9-149.1)         Mean $\pm$ SD       0.9 $\pm$ 1.5       1.1 $\pm$ 1.6       0.9 $\pm$ 1.5       0.34         Median (IQR)       0 (0-2)       0 (0-3)       0 (0-1)         Face       Mean $\pm$ SD       0.4 $\pm$ 0.8       0.5 $\pm$ 1.0       0.3 $\pm$ 0.8       0.32         Median (IQR)       0 (0-0)       0 (0-0)       0 (0-0)       0 (0-0)       Chest         Mean $\pm$ SD       1.4 $\pm$ 1.7       1.6 $\pm$ 1.6       1.3 $\pm$ 1.7       0.27         Median (IQR)       0 (0-2)       0 (0-2)       0 (0-3)       Chest         Mean $\pm$ SD       1 $\pm$ 1.5       0.9 $\pm$ 1.4       1.1 $\pm$ 1.6       0.62         Median (IQR)       0 (0-2)       0 (0-2)       0 (0-3)       Externity         Mean $\pm$ SD       1 $\pm$ 1.5       0.9 $\pm$ 1.4       1.1 $\pm$ 1.6       0.62         Median (IQR)       3 (2-3)       3 (2-3)       3 (2-3)       3 (2-3)         Extremity       Mean $\pm$ SD       0.9 $\pm$ 0.6       <	Median (IQR)	1.9 (1.7-2.0)	1.9 (1.7-2.0)	1.9 (1.7-2.0)	
Mean $\pm$ SD130.4 $\pm$ 58.7139.1 $\pm$ 66.0125.4 $\pm$ 53.80.28Median (IQR)121.3132.9118.9(93.8-155.8)(93.8-171.6)(94.9-149.1)AIS ScoreHead/Neck(94.9-149.1)Mean $\pm$ SD0.9 $\pm$ 1.51.1 $\pm$ 1.60.9 $\pm$ 1.5Mean $\pm$ SD0.9 $\pm$ 1.51.1 $\pm$ 1.60.9 $\pm$ 1.5Median (IQR)0 (0-2)0 (0-3)0 (0-1)FaceMedian (IQR)0 (0-0)0 (0-0)Mean $\pm$ SD0.4 $\pm$ 0.80.5 $\pm$ 1.00.3 $\pm$ 0.8Median (IQR)0 (0-0)0 (0-0)0 (0-0)ChestMean $\pm$ SD1.4 $\pm$ 1.71.6 $\pm$ 1.61.3 $\pm$ 1.7Mean $\pm$ SD1.4 $\pm$ 1.71.6 $\pm$ 1.61.3 $\pm$ 1.70.27Median (IQR)0 (0-2)0 (0-2)0 (0-3)1Abdomen/PelvisMean $\pm$ SD1.5 $\pm$ 1.50.9 $\pm$ 1.41.1 $\pm$ 1.60.62Median (IQR)0 (0-2)0 (0-2)0 (0-3)2.7 $\pm$ 0.60.52Median (IQR)3 (2-3)3 (2-3)3 (2-3)32.7 $\pm$ 0.6ExtremityMean $\pm$ SD0.9 $\pm$ 0.60.8 $\pm$ 0.60.9 $\pm$ 0.60.94Median (IQR)1 (0-1)1 (0-1)1 (0-1)1ISSMean $\pm$ SD19.6 $\pm$ 13.619.1 $\pm$ 11.019.9 $\pm$ 14.90.64Median (IQR)17 (10-27)18 (10-24)14 (9-29)0.64Median (IQR)15.7 $\pm$ 14.416.5 $\pm$ 16.915.3 $\pm$ 12.80.98Median (IQR)15.7 $\pm$ 14.4 <td>CrCl, mL/min</td> <td></td> <td></td> <td></td> <td></td>	CrCl, mL/min				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		$130.4 \pm 58.7$	$139.1 \pm 66.0$	$125.4 \pm 53.8$	0.28
AIS Score Head/Neck Mean $\pm$ SD 0.9 $\pm$ 1.5 1.1 $\pm$ 1.6 0.9 $\pm$ 1.5 0.34 Median (IQR) 0 (0-2) 0 (0-3) 0 (0-1) Face Mean $\pm$ SD 0.4 $\pm$ 0.8 0.5 $\pm$ 1.0 0.3 $\pm$ 0.8 0.32 Median (IQR) 0 (0-0) 0 (0-0) 0 (0-0) Chest Mean $\pm$ SD 1.4 $\pm$ 1.7 1.6 $\pm$ 1.6 1.3 $\pm$ 1.7 0.27 Median (IQR) 0 (0-3) 1 (0-3) 0 (0-3) Abdomen/Pelvis Mean $\pm$ SD 1 $\pm$ 1.5 0.9 $\pm$ 1.4 1.1 $\pm$ 1.6 0.62 Median (IQR) 0 (0-2) 0 (0-2) 0 (0-3) Extremity Mean $\pm$ SD 2.6 $\pm$ 0.7 2.6 $\pm$ 0.8 2.7 $\pm$ 0.6 0.52 Median (IQR) 3 (2-3) 3 (2-3) 3 (2-3) Extremal Mean $\pm$ SD 0.9 $\pm$ 0.6 0.8 $\pm$ 0.6 0.9 $\pm$ 0.6 0.94 Median (IQR) 1 (0-1) 1 (0-1) 1 (0-1) ISS Mean $\pm$ SD 19.6 $\pm$ 13.6 19.1 $\pm$ 11.0 19.9 $\pm$ 14.9 0.64 Median (IQR) 17 (10-27) 18 (10-24) 14 (9-29) Outcomes Hospital LOS, d Mean $\pm$ SD 15.7 $\pm$ 14.4 16.5 $\pm$ 16.9 15.3 $\pm$ 12.8 0.98 Median (IQR) 11 (6-20) 12 (6-22) 10 (7-19.5) ICU LOS, d Mean $\pm$ SD 6.9 $\pm$ 7.3 7.5 $\pm$ 7.3 6.6 $\pm$ 7.4 0.37 Median (IQR) 4 (2-9) 4 (3-12) 3.5 (2-7) Required ICU 112 (70.4) 42 (72.4) 70 (69.3) 0.82 care, n (%) Mortality, No. 1 (0.6) 0 1 (1.0) > 0.9	Median (IQR)				
Head/Neck         Mean $\pm$ SD $0.9 \pm 1.5$ $1.1 \pm 1.6$ $0.9 \pm 1.5$ $0.34$ Median (IQR) $0 (0-2)$ $0 (0-3)$ $0 (0-1)$ Face       Mean $\pm$ SD $0.4 \pm 0.8$ $0.5 \pm 1.0$ $0.3 \pm 0.8$ $0.32$ Median (IQR) $0 (0-0)$ $0 (0-0)$ $0 (0-0)$ $0 (0-0)$ Chest       Mean $\pm$ SD $1.4 \pm 1.7$ $1.6 \pm 1.6$ $1.3 \pm 1.7$ $0.27$ Median (IQR) $0 (0-3)$ $1 (0-3)$ $0 (0-3)$ $0 (0-3)$ Abdomen/Pelvis       Mean $\pm$ SD $1 \pm 1.5$ $0.9 \pm 1.4$ $1.1 \pm 1.6$ $0.62$ Median (IQR) $0 (0-2)$ $0 (0-2)$ $0 (0-3)$ Extermity       Mean $\pm$ SD $2.6 \pm 0.7$ $2.6 \pm 0.8$ $2.7 \pm 0.6$ $0.52$ Median (IQR) $3 (2-3)$ $3 (2-3)$ $3 (2-3)$ $3 (2-3)$ External         Mean $\pm$ SD $0.9 \pm 0.6$ $0.8 \pm 0.6$ $0.9 \pm 0.6$ $0.94$ Median (IQR) $1 (0-1)$ $1 (0-1)$ $1 (0-1)$ ISS       Mean $\pm$ SD $19.6 \pm 13.6$ $19.1 \pm 11.0$ $19.9 \pm 14.9$ $0.64$ Median (IQR) <td></td> <td>(93.8–155.8)</td> <td>(93.8–171.6)</td> <td>(94.9–149.1)</td> <td></td>		(93.8–155.8)	(93.8–171.6)	(94.9–149.1)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	AIS Score	. ,	, ,		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Head/Neck				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Mean ± SD	$0.9 \pm 1.5$	$1.1 \pm 1.6$	$0.9 \pm 1.5$	0.34
Face Mean $\pm$ SD 0.4 $\pm$ 0.8 0.5 $\pm$ 1.0 0.3 $\pm$ 0.8 0.32 Median (IQR) 0 (0-0) 0 (0-0) 0 (0-0) Chest Mean $\pm$ SD 1.4 $\pm$ 1.7 1.6 $\pm$ 1.6 1.3 $\pm$ 1.7 0.27 Median (IQR) 0 (0-3) 1 (0-3) 0 (0-3) Abdomen/Pelvis Mean $\pm$ SD 1 $\pm$ 1.5 0.9 $\pm$ 1.4 1.1 $\pm$ 1.6 0.62 Median (IQR) 0 (0-2) 0 (0-2) 0 (0-3) Extremity Mean $\pm$ SD 2.6 $\pm$ 0.7 2.6 $\pm$ 0.8 2.7 $\pm$ 0.6 0.52 Median (IQR) 3 (2-3) 3 (2-3) 3 (2-3) External Mean $\pm$ SD 0.9 $\pm$ 0.6 0.8 $\pm$ 0.6 0.9 $\pm$ 0.6 0.94 Median (IQR) 1 (0-1) 1 (0-1) 1 (0-1) ISS Mean $\pm$ SD 19.6 $\pm$ 13.6 19.1 $\pm$ 11.0 19.9 $\pm$ 14.9 0.64 Median (IQR) 17 (10-27) 18 (10-24) 14 (9-29) Outcomes Hospital LOS, d Mean $\pm$ SD 6.9 $\pm$ 7.3 7.5 $\pm$ 7.3 6.6 $\pm$ 7.4 0.37 Median (IQR) 4 (2-9) 4 (3-12) 3.5 (2-7) Required ICU 112 (70.4) 42 (72.4) 70 (69.3) 0.82 care, n (%) Mortality, No. 1 (0.6) 0 1 (1.0) > 0.9					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Face			/	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		$0.4 \pm 0.8$	$0.5 \pm 1.0$	$0.3 \pm 0.8$	0.32
Chest Mean $\pm$ SD 1.4 $\pm$ 1.7 1.6 $\pm$ 1.6 1.3 $\pm$ 1.7 0.27 Median (IQR) 0 (0-3) 1 (0-3) 0 (0-3) Abdomen/Pelvis Mean $\pm$ SD 1 $\pm$ 1.5 0.9 $\pm$ 1.4 1.1 $\pm$ 1.6 0.62 Median (IQR) 0 (0-2) 0 (0-2) 0 (0-3) Extremity Mean $\pm$ SD 2.6 $\pm$ 0.7 2.6 $\pm$ 0.8 2.7 $\pm$ 0.6 0.52 Median (IQR) 3 (2-3) 3 (2-3) 3 (2-3) Extremal Mean $\pm$ SD 0.9 $\pm$ 0.6 0.8 $\pm$ 0.6 0.9 $\pm$ 0.6 0.94 Median (IQR) 1 (0-1) 1 (0-1) 1 (0-1) ISS Mean $\pm$ SD 19.6 $\pm$ 13.6 19.1 $\pm$ 11.0 19.9 $\pm$ 14.9 0.64 Median (IQR) 17 (10-27) 18 (10-24) 14 (9-29) Outcomes Hospital LOS, d Mean $\pm$ SD 6.9 $\pm$ 7.3 7.5 $\pm$ 7.3 6.6 $\pm$ 7.4 0.37 Median (IQR) 4 (2-9) 4 (3-12) 3.5 (2-7) Required ICU 112 (70.4) 42 (72.4) 70 (69.3) 0.82 care, n (%) Mortality, No. 1 (0.6) 0 1 (1.0) > 0.9					
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Chest	0 (0 0)	0 (0 0)	0 (0 0)	
Median (IQR)0 (0-3)1 (0-3)0 (0-3)Abdomen/PelvisMean $\pm$ SD1 $\pm$ 1.50.9 $\pm$ 1.41.1 $\pm$ 1.60.62Median (IQR)0 (0-2)0 (0-2)0 (0-3)ExtremityMean $\pm$ SD2.6 $\pm$ 0.72.6 $\pm$ 0.82.7 $\pm$ 0.60.52Median (IQR)3 (2-3)3 (2-3)3 (2-3)ExternalMean $\pm$ SD0.9 $\pm$ 0.60.8 $\pm$ 0.60.9 $\pm$ 0.60.94Median (IQR)1 (0-1)1 (0-1)1 (0-1)ISSMean $\pm$ SD19.6 $\pm$ 13.619.1 $\pm$ 11.019.9 $\pm$ 14.90.64Median (IQR)17 (10-27)18 (10-24)14 (9-29)OutcomesHospital LOS, dMean $\pm$ SD15.7 $\pm$ 14.416.5 $\pm$ 16.915.3 $\pm$ 12.80.98Median (IQR)11 (6-20)12 (6-22)10 (7-19.5)ICU LOS, dMean $\pm$ SD6.9 $\pm$ 7.37.5 $\pm$ 7.36.6 $\pm$ 7.40.37Median (IQR)4 (2-9)4 (3-12)3.5 (2-7)Required ICU112 (70.4)42 (72.4)70 (69.3)0.82care, n (%)Mortality, No.1 (0.6)01 (1.0)> 0.9		$1.4 \pm 1.7$	$1.6 \pm 1.6$	$1.3 \pm 1.7$	0.27
Abdomen/Pelvis         Mean $\pm$ SD       1 $\pm$ 1.5       0.9 $\pm$ 1.4       1.1 $\pm$ 1.6       0.62         Median (IQR)       0 (0-2)       0 (0-2)       0 (0-3)         Extremity       Mean $\pm$ SD       2.6 $\pm$ 0.7       2.6 $\pm$ 0.8       2.7 $\pm$ 0.6       0.52         Median (IQR)       3 (2-3)       3 (2-3)       3 (2-3)       3       2.3         External       Nean $\pm$ SD       0.9 $\pm$ 0.6       0.8 $\pm$ 0.6       0.9 $\pm$ 0.6       0.94         Median (IQR)       1 (0-1)       1 (0-1)       1 (0-1)       1 (0-1)         ISS       Mean $\pm$ SD       19.6 $\pm$ 13.6       19.1 $\pm$ 11.0       19.9 $\pm$ 14.9       0.64         Median (IQR)       17 (10-27)       18 (10-24)       14 (9-29)       0         Outcomes       Use 15.7 $\pm$ 14.4       16.5 $\pm$ 16.9       15.3 $\pm$ 12.8       0.98         Median (IQR)       11 (6-20)       12 (6-22)       10 (7-19.5)       102         ICU LOS, d       Mean $\pm$ SD       6.9 $\pm$ 7.3       7.5 $\pm$ 7.3       6.6 $\pm$ 7.4       0.37         Median (IQR)       4 (2-9)       4 (3-12)       3.5 (2-7)       Required ICU       112 (70.4)       42 (72.4)       70 (69.3)       0.82         Care, n (%)       Mortality, No. <td></td> <td></td> <td></td> <td></td> <td>0.2/</td>					0.2/
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		0 (0 0)	1 (0 0)	0 (0 0)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		1 + 15	0.9 + 1.4	1.1 + 1.6	0.62
Extremity Mean $\pm$ SD 2.6 $\pm$ 0.7 2.6 $\pm$ 0.8 2.7 $\pm$ 0.6 0.52 Median (IQR) 3 (2–3) 3 (2–3) 3 (2–3) External Mean $\pm$ SD 0.9 $\pm$ 0.6 0.8 $\pm$ 0.6 0.9 $\pm$ 0.6 0.94 Median (IQR) 1 (0–1) 1 (0–1) 1 (0–1) ISS Mean $\pm$ SD 19.6 $\pm$ 13.6 19.1 $\pm$ 11.0 19.9 $\pm$ 14.9 0.64 Median (IQR) 17 (10–27) 18 (10–24) 14 (9–29) Outcomes Hospital LOS, d Mean $\pm$ SD 15.7 $\pm$ 14.4 16.5 $\pm$ 16.9 15.3 $\pm$ 12.8 0.98 Median (IQR) 11 (6–20) 12 (6–22) 10 (7–19.5) ICU LOS, d Mean $\pm$ SD 6.9 $\pm$ 7.3 7.5 $\pm$ 7.3 6.6 $\pm$ 7.4 0.37 Median (IQR) 4 (2–9) 4 (3–12) 3.5 (2–7) Required ICU 112 (70.4) 42 (72.4) 70 (69.3) 0.82 care, n (%) Mortality, No. 1 (0.6) 0 1 (1.0) > 0.9					5.62
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		0 (0 2)	0 (0 2)	0 (0 0)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	•	$2.6 \pm 0.7$	$2.6 \pm 0.8$	$2.7 \pm 0.6$	0.52
External Mean $\pm$ SD 0.9 $\pm$ 0.6 0.8 $\pm$ 0.6 0.9 $\pm$ 0.6 0.94 Median (IQR) 1 (0-1) 1 (0-1) 1 (0-1) ISS Mean $\pm$ SD 19.6 $\pm$ 13.6 19.1 $\pm$ 11.0 19.9 $\pm$ 14.9 0.64 Median (IQR) 17 (10-27) 18 (10-24) 14 (9-29) Outcomes Hospital LOS, d Mean $\pm$ SD 15.7 $\pm$ 14.4 16.5 $\pm$ 16.9 15.3 $\pm$ 12.8 0.98 Median (IQR) 11 (6-20) 12 (6-22) 10 (7-19.5) ICU LOS, d Mean $\pm$ SD 6.9 $\pm$ 7.3 7.5 $\pm$ 7.3 6.6 $\pm$ 7.4 0.37 Median (IQR) 4 (2-9) 4 (3-12) 3.5 (2-7) Required ICU 112 (70.4) 42 (72.4) 70 (69.3) 0.82 care, n (%) Mortality, No. 1 (0.6) 0 1 (1.0) > 0.9					0.02
$\begin{array}{cccccccccccccccccccccccccccccccccccc$		0 (2 0)	0 (2 0)	0 (20)	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		09 + 06	$08 \pm 06$	09 + 06	0.94
$ \begin{array}{llllllllllllllllllllllllllllllllllll$					5.74
		1 (0-1)	1 (0-1)	1 (0-1)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		196 + 136	191 + 110	199 + 140	0.64
Outcomes           Hospital LOS, d           Mean $\pm$ SD         15.7 $\pm$ 14.4         16.5 $\pm$ 16.9         15.3 $\pm$ 12.8         0.98           Median (IQR)         11 (6-20)         12 (6-22)         10 (7-19.5)           ICU LOS, d         Mean $\pm$ SD         6.9 $\pm$ 7.3         7.5 $\pm$ 7.3         6.6 $\pm$ 7.4         0.37           Median (IQR)         4 (2-9)         4 (3-12)         3.5 (2-7)         Required ICU         112 (70.4)         42 (72.4)         70 (69.3)         0.82           care, n (%)         Mortality, No.         1 (0.6)         0         1 (1.0)         > 0.9					0.04
		1, (10-27)	10 (10-24)	11 ()-4))	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	· ·	157 + 144	165 + 160	153 + 198	0 05
ICU LOS, d       Mean $\pm$ SD $6.9 \pm 7.3$ $7.5 \pm 7.3$ $6.6 \pm 7.4$ $0.37$ Median (IQR)       4 (2–9)       4 (3–12) $3.5 (2–7)$ Required ICU       112 (70.4)       42 (72.4)       70 (69.3) $0.82$ care, n (%)       0       1 (1.0)       > 0.9					0.98
		11 (0-20)	12 (0-22)	10 (7-19.5)	
Median (IQR)         4 (2–9)         4 (3–12)         3.5 (2–7)           Required ICU         112 (70.4)         42 (72.4)         70 (69.3)         0.82           care, n (%)         Mortality, No.         1 (0.6)         0         1 (1.0)         > 0.9		60 - 70	76 + 79	66 + 74	0.07
Required ICU         112 (70.4)         42 (72.4)         70 (69.3)         0.82           care, n (%)         0         1 (0.6)         0         1 (1.0)         > 0.9					0.37
care, n (%) Mortality, No. 1 (0.6) 0 1 (1.0) > 0.9					0.00
Mortality, No. 1 (0.6) 0 1 (1.0) > 0.9	-	112 (/0.4)	42 (72.4)	/0 (09.3)	0.82
-		1 (0 ()	0	1 (1 (2)	
	Mortality, No. (%)	1 (0.6)	U	1 (1.0)	> 0.99

Abbreviations: AIS Abbreviated Injury Scale; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); BSA, body surface area; CrCl, creatinine clearance; IQR, interquartile range; ISS, Injury Severity Score; LOS, length of stay; SD, standard deviation.

patients (69.8%) were male. The cohorts were similar with respect to age, sex, race, and injury severity (Table 1). The proportion of patients afflicted with blunt injury and the specific mechanisms were also comparable (Table 2). The resulting orthopedic injuries and operative interventions required to address those specific injuries were also similar among CONTROL and ADJUST. The most common injuries afflicting this population overall included pelvic (34%), femur (30.2%), and tibial (30.2%) fractures. Similar proportions of these fractures were appreciated in both cohorts. Overall, 70.4% of patients required operative treatment. If operative treatment was required, patients most

Download English Version:

# https://daneshyari.com/en/article/8831967

Download Persian Version:

https://daneshyari.com/article/8831967

Daneshyari.com